Australia markets open in 10 hours

Genetic Technologies Limited (GTG.AX)

ASX - ASX Delayed price. Currency in AUD
Add to watchlist
0.00300.0000 (0.00%)
At close: 02:30PM AEST
Full screen
Previous close0.0030
Open0.0030
Bid0.0030 x 10000000
Ask0.0040 x 249000000
Day's range0.0030 - 0.0030
52-week range0.0030 - 0.0100
Volume1,501,000
Avg. volume3,825,724
Market cap27.702M
Beta (5Y monthly)1.25
PE ratio (TTM)N/A
EPS (TTM)-0.0010
Earnings date29 Aug 2022 - 02 Sept 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est0.25
  • GlobeNewswire

    Transformational Pathway to US Payer System; Attributing US$1.4 Billion Health and Economic Benefit from geneType Breast Cancer Risk Assessment Test

    MELBOURNE, Australia, June 16, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease is delighted to announce the completion of an independently developed and validated customizable Budget Impact Model (BIM), which demonstrates significant health and economic benefits directly attributed to the implementation of geneType Breast Cancer Risk Assessment Test. Breast cancer ri

  • GlobeNewswire

    Acquisition of global direct to consumer ecommerce business

    MELBOURNE, Australia, May 16, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GENE”), a global leader in genomics-based tests in health, wellness and serious disease advises that it has entered into an agreement to acquire the direct-to-consumer eCommerce business and distribution rights associated with AffinityDNA. Acquisition Highlights Strategic acquisition continues to strengthen the direct-to-consumer channel for GENE.Provides an additional platfor

  • GlobeNewswire

    Genetic Technologies drives leadership in precision medicine with Multi-Risk Test

    MELBOURNE, Australia, April 08, 2022 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE, ASX: GTG) (“GENE” or the “Company”), a global leader in genomics-based tests in health, wellness and serious disease provides its year to date results for the nine months ended March 31, 2022. Key Highlights Year to date growth in revenue of 475%Cash receipts of A$2 million in quarter 3, an increase of 9% on the prior quarter, and mainly comprising EasyDNA product salesGeneType Multi-Risk Test re